HPV16 E6 Gene Transcripts in Primary Type II Endometrial Carcinomas

Area of Science:

• Gynecologic Oncology
• Virology
• Molecular Pathology

Background:

• Limited data exists on human papillomavirus (HPV) DNA prevalence across different endometrial carcinoma (EC) subtypes.
• Understanding HPV's role in EC pathogenesis is crucial for targeted therapies.

Purpose of the Study:

• To investigate the incidence of HPV16 DNA E6/E7 transcripts in various EC subtypes.
• To determine if HPV16 E6/E7 transcripts correlate with specific EC clinicopathological features.
• To examine the presence of HPV16 in lymph node metastases of EC.

Main Methods:

• Polymerase chain reaction (PCR)-based technology was used to detect HPV16 DNA E6/E7 transcripts.
• Immunohistochemical staining was performed on HPV16-positive cases.
• Seven lymph node metastases were analyzed for HPV16 DNA E6/E7.

Main Results:

• HPV16 E6 transcripts were detected in 50% of type II (non-endometrioid) ECs, including papillary-serous and clear-cell subtypes.
• No HPV16 E6 transcripts were found in type I (endometrioid) ECs.
• HPV16 E7 transcripts and HPV16 DNA in lymph node metastases were not detected in any cases.
• A statistically significant difference in HPV16 E6 transcripts was observed between endometrioid and non-endometrioid ECs (p=0.0011).

Conclusions:

• HPV16 E6 gene transcripts are primarily associated with non-endometrioid (type II) endometrial carcinoma subtypes.
• The absence of HPV E6/E7 DNA transcripts in lymph node metastases suggests limited systemic spread via this mechanism.
• Findings highlight subtype-specific roles of HPV in endometrial carcinogenesis.